Author： Hedlund Jonas Örtqvist Åke Konradsen Helle Bossen Kalin Mats
Publisher： Informa Healthcare
ISSN： 0036-5548
Source： Scandinavian Journal of Infectious Diseases, Vol.32, Iss.3, 2000-10, pp. : 281-286
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
We have recently studied the efficacy of pneumococcal vaccine in preventing pneumonia recurrences after hospital treatment for community-acquired pneumonia in non-immunocompromised patients aged 50-85 y. Among these patients, we have now compared the antibody response to the pneumococcal vaccine between patients who developed pneumonia (n=50) and patients without pneumonia recurrences (n=100), during a mean follow-up period of 32 months after vaccination. The antibody levels of 5 pneumococcal serotypes were measured before, and 4 weeks, 1 y and 3 y after vaccination. A lower risk of pneumonia recurrences was seen in patients with antibody fold increases (FIs) >4 from pre-vaccination to post-vaccination compared with patients with lower FIs (p=0.02). The results suggest that in this patient category, the antibody response to pneumococcal vaccination is of importance for the risk of pneumonia recurrence.
Related content
The Electroencephalogram in the Middle‐Aged and the Elderly
JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 25, Iss. 4, 1977-04 ,pp. :
Access to resources
Recommend
Nosocomial Pneumococcal Pneumonia in the Elderly
JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 29, Iss. 7, 1981-07 ,pp. :
Correlates of Cognitive Function in Middle-Aged Adults
Gerontology, Vol. 44, Iss. 2, 1998-02 ,pp. :